Evidence map›Paper›PMID 31080772›Full record

ReviewTranslational andrology and urology2019

Current protocols and outcomes of ABO-incompatible kidney transplantation based on a single-center experience.

Masayoshi Okumi, Yoichi Kakuta, Kohei Unagami, Toshio Takagi, Junpei Iizuka, Masashi Inui, Hideki Ishida, Kazunari Tanabe

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational andrology and urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Differences between xenotransplantation and allogeneic kidney transplantation: the current situation and future challenges in Japan.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025
    Review
  3. Article
  4. Article
  5. Higher Donor Age and Severe Microvascular Inflammation Are Risk Factors for Chronic Rejection After Treatment of Active Antibody-Mediated Rejection.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Masayoshi OkumiDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Yoichi KakutaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Kohei UnagamiDepartment of Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Toshio TakagiDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Junpei IizukaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Masashi InuiDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Hideki IshidaDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Kazunari TanabeDepartment of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ABO-incompatible living kidney transplantation (ABO-ILKT) is an effective option for increasing living kidney transplant opportunities. ABO-ILKT has been conducted in our institution since 1989 to widen the indication for living kidney transplantation. ABO-ILKT is considered to require extra treatment, and it has increased risks compared with ABO-compatible living kidney transplantation (ABO-CLKT). In the past two decades, some protocols have removed anti-blood-type antibodies to prevent the production of antibodies. Additionally, we have made considerable changes to our ABO-ILKT protocol as new immunosuppressive agents have been developed. Consequently, increased immunosuppression and immunological understanding have helped shape recent desensitization protocols. Herein, we review the history, therapeutic strategy, pathology, and future directions of ABO-ILKT. Our standard immunosuppressive regimen and desensitization protocol for ABO-ILKT recipients consist of low doses of tacrolimus (TAC), mycophenolate mofetil (MMF), and rituximab; several sessions of double filtration plasmapheresis; and basiliximab induction. We do not use thymoglobulin induction, intravenous immunoglobulin, or prophylactic post-transplant plasmapheresis. Recently, ABO-ILKT has been recognized as a useful alternative therapy for end-stage kidney disease with ABO-incompatibility, and its outcome is comparable to that of ABO-CLKT.

Indexed as

ABO incompatibilitydesensitizationimmunosuppressionliving kidney transplantation

Identifiers

PMID31080772
PMCPMC6503224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.